© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer
Affiliation of authors: Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles.
Correspondence to: Dennis J. Slamon, MD, PhD, University of California, Los Angeles, Peter Ueberroth Bldg. 3360B, 10945 Le Conte Ave., Los Angeles, CA 90095-7077 (e-mail: dslamon{at}mednet.ucla.edu)
Background: Trastuzumab, a humanized anti-HER2 antibody, increases the clinical benefit of first-line chemotherapy in patients with metastatic breast cancers that overexpress HER2. We characterized interactions between trastuzumab and chemotherapeutic agents commonly used in the treatment of breast cancer. Methods: Multiple drug effect/combination index isobologram analysis was used to study the efficacy of chemotherapeutic drug plus trastuzumab combinations tested against four HER2-overexpressing breast cancer cell lines (SK-BR-3, BT-474, MDA-MB-361, and MDA-MB-453). Combination index values were derived from parameters of the median effect plots, and statistical tests were used to determine whether the mean combination index values at multiple effect levels were statistically significantly different from a combination index value of 1.0. Values less than 1.0 indicate synergistic interactions, values greater than 1.0 indicate antagonistic interactions, and values equal to 1.0 indicate additive interactions. Results: At a wide range of clinically achievable drug concentrations, synergistic interactions were observed in all four breast cancer cell lines for trastuzumab plus carboplatin (mean combination index values ranged from 0.32 [P<.001] to 0.53 [P<.001]), 4-hydroxycyclophosphamide (mean combination index values ranged from 0.38 [P<.001] to 0.73 [P = .010]), docetaxel (mean combination index values ranged from 0.30 [P<.001] to 0.62 [P<.001]), and vinorelbine (mean combination index values ranged from 0.24 [P<.001] to 0.78 [P<.034]). Additive interactions were observed in all four cell lines with trastuzumab plus doxorubicin, epirubicin, and paclitaxel. Interactions between trastuzumab and gemcitabine were synergistic at low concentrations of gemcitabine and antagonistic at high concentrations. A synergistic interaction was observed with a three-drug combination of docetaxel plus carboplatin plus trastuzumab in SK-BR-3 cells (mean combination index value = 0.09; P<.001). Conclusion: Consistent synergistic interactions of trastuzumab plus carboplatin, 4-hydroxycyclophosphamide, docetaxel, or vinorelbine across a wide range of clinically relevant concentrations in HER2-overexpressing breast cancer cells indicate that these are rational combinations to test in human clinical trials.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- HERe-2 Stay: The Continuing Importance of Translational Research in Breast Cancer
- George W. Sledge, Jr.
J Natl Cancer Inst 2004 96: 725-727.[Extract] [Full Text] [PDF]
Related Article in JNCI
- Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer
- Mark D. Pegram, Tadeusz Pienkowski, Donald W. Northfelt, Wolfgang Eiermann, Ravi Patel, Pierre Fumoleau, Eleonor Quan, John Crown, Deborah Toppmeyer, Michael Smylie, Alessandro Riva, Sandra Blitz, Michael F. Press, David Reese, Mary-Ann Lindsay, and Dennis J. Slamon
J Natl Cancer Inst 2004 96: 759-769.[Abstract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  J. H. Kim, E. S. Ko, D. Y. Kim, H. Han, J.-H. Sohn, and D. H. Choe Noncalcified Ductal Carcinoma In Situ: Imaging and Histologic Findings in 36 Tumors J. Ultrasound Med., July 1, 2009; 28(7): 903 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Yao, W. Zhou, S. T. Lee-Hoeflich, T. Truong, P. M. Haverty, J. Eastham-Anderson, N. Lewin-Koh, B. Gunter, M. Belvin, L. J. Murray, et al. Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab Clin. Cancer Res., June 15, 2009; 15(12): 4147 - 4156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Corkery, J. Crown, M. Clynes, and N. O'Donovan Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer Ann. Onc., May 1, 2009; 20(5): 862 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. von Minckwitz, A. du Bois, M. Schmidt, N. Maass, T. Cufer, F. E. de Jongh, E. Maartense, C. Zielinski, M. Kaufmann, W. Bauer, et al. Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study J. Clin. Oncol., April 20, 2009; 27(12): 1999 - 2006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zeng, D. Sachdev, H. Zhang, M. Gaillard-Kelly, and D. Yee Sequencing of Type I Insulin-Like Growth Factor Receptor Inhibition Affects Chemotherapy Response In vitro and In vivo Clin. Cancer Res., April 15, 2009; 15(8): 2840 - 2849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Staal, M. J. O'Connell, and C. J. Allegra The Marriage of Growth Factor Inhibitors and Chemotherapy: Bliss or Bust? J. Clin. Oncol., April 1, 2009; 27(10): 1545 - 1548. [Full Text] [PDF]
|
|
|
|
 |
|
 S. MIYAMOTO, T. FUKAMI, H. YAGI, M. KUROKI, and F. YOTSUMOTO Potential for Molecularly Targeted Therapy against Epidermal Growth Factor Receptor Ligands Anticancer Res, March 1, 2009; 29(3): 823 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Press, R. S. Finn, D. Cameron, A. Di Leo, C. E. Geyer, I. E. Villalobos, A. Santiago, R. Guzman, A. Gasparyan, Y. Ma, et al. HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer Clin. Cancer Res., December 1, 2008; 14(23): 7861 - 7870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Rayson, D. Richel, S. Chia, C. Jackisch, S. van der Vegt, and T. Suter Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies Ann. Onc., September 1, 2008; 19(9): 1530 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Bullock and K. Blackwell Clinical Efficacy of Taxane-Trastuzumab Combination Regimens for HER-2-Positive Metastatic Breast Cancer Oncologist, May 1, 2008; 13(5): 515 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Catania, M. Medici, E. Magni, E. Munzone, D. Cardinale, L. Adamoli, G. Sanna, I. Minchella, D. Radice, A. Goldhirsch, et al. Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination Ann. Onc., December 1, 2007; 18(12): 1969 - 1975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Taylor, D. Hershman, N. Shah, N. Suciu-Foca, D. P. Petrylak, R. Taub, L. Vahdat, B. Cheng, M. Pegram, K. L. Knutson, et al. Augmented HER-2 Specific Immunity during Treatment with Trastuzumab and Chemotherapy Clin. Cancer Res., September 1, 2007; 13(17): 5133 - 5143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-A. Pearson, C. L. Ringland, and R. L. Ward Trastuzumab and Metastatic Breast Cancer: Trastuzumab Use in Australia Monitoring the Effect of an Expensive Medicine Access Program J. Clin. Oncol., August 20, 2007; 25(24): 3688 - 3693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Coudert, R. Largillier, L. Arnould, P. Chollet, M. Campone, D. Coeffic, F. Priou, J. Gligorov, X. Martin, V. Trillet-Lenoir, et al. Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2 Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial J. Clin. Oncol., July 1, 2007; 25(19): 2678 - 2684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Chan A review of the use of trastuzumab (Herceptin(R)) plus vinorelbine in metastatic breast cancer Ann. Onc., July 1, 2007; 18(7): 1152 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Marangoni, A. Vincent-Salomon, N. Auger, A. Degeorges, F. Assayag, P. de Cremoux, L. de Plater, C. Guyader, G. De Pinieux, J.-G. Judde, et al. A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays Clin. Cancer Res., July 1, 2007; 13(13): 3989 - 3998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gori, S. Rimondini, V. De Angelis, M. Colozza, G. Bisagni, G. Moretti, A. Sidoni, C. Basurto, C. Aristei, P. Anastasi, et al. Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors Oncologist, July 1, 2007; 12(7): 766 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H.A. Hussain, G. R. MacVicar, D. P. Petrylak, R. L. Dunn, U. Vaishampayan, P. N. Lara Jr, G. S. Chatta, D. M. Nanus, L. M. Glode, D. L. Trump, et al. Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu-Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial J. Clin. Oncol., June 1, 2007; 25(16): 2218 - 2224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Limentani, A. M. Brufsky, J. K. Erban, M. Jahanzeb, and D. Lewis Phase II Study of Neoadjuvant Docetaxel, Vinorelbine, and Trastuzumab Followed by Surgery and Adjuvant Doxorubicin Plus Cyclophosphamide in Women With Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancer J. Clin. Oncol., April 1, 2007; 25(10): 1232 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Tripathy Capecitabine in Combination with Novel Targeted Agents in the Management of Metastatic Breast Cancer: Underlying Rationale and Results of Clinical Trials Oncologist, April 1, 2007; 12(4): 375 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. U. Buzdar, V. Valero, N. K. Ibrahim, D. Francis, K. R. Broglio, R. L. Theriault, L. Pusztai, M. C. Green, S. E. Singletary, K. K. Hunt, et al. Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen Clin. Cancer Res., January 1, 2007; 13(1): 228 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Menendez, I. Mehmi, and R. Lupu Trastuzumab in Combination With Heregulin-Activated Her-2 (erbB-2) Triggers a Receptor-Enhanced Chemosensitivity Effect in the Absence of Her-2 Overexpression J. Clin. Oncol., August 10, 2006; 24(23): 3735 - 3746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ferretti, P. Papaldo, A. Fabi, P. Carlini, A. Felici, and F. Cognetti Adjuvant Trastuzumab with Docetaxel or Vinorelbine for HER-2-Positive Breast Cancer Oncologist, July 1, 2006; 11(7): 853 - 854. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Spankuch, S. Heim, E. Kurunci-Csacsko, C. Lindenau, J. Yuan, M. Kaufmann, and K. Strebhardt Down-regulation of Polo-like Kinase 1 Elevates Drug Sensitivity of Breast Cancer Cells In vitro and In vivo Cancer Res., June 1, 2006; 66(11): 5836 - 5846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Papaldo, A. Fabi, G. Ferretti, M. Mottolese, A. M. Cianciulli, B. Di Cocco, M. S. Pino, P. Carlini, S. Di Cosimo, I. Sacchi, et al. A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease Ann. Onc., April 1, 2006; 17(4): 630 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Montemurro, M. Donadio, M. Clavarezza, S. Redana, M. E. Jacomuzzi, G. Valabrega, S. Danese, G. Vietti-Ramus, A. Durando, M. Venturini, et al. Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based Therapy. Oncologist, April 1, 2006; 11(4): 318 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Kabe and J. M. Kolesar Role of trastuzumab in adjuvant therapy for locally invasive breast cancer Am. J. Health Syst. Pharm., March 15, 2006; 63(6): 527 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Joensuu, P.-L. Kellokumpu-Lehtinen, P. Bono, T. Alanko, V. Kataja, R. Asola, T. Utriainen, R. Kokko, A. Hemminki, M. Tarkkanen, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med., February 23, 2006; 354(8): 809 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O'Shaughnessy Extending Survival with Chemotherapy in Metastatic Breast Cancer Oncologist, October 1, 2005; 10(suppl_3): 20 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, M. Tubiana-Hulin, S. Chan, D. Grimes, A. Anton, A. Lluch, et al. Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group J. Clin. Oncol., July 1, 2005; 23(19): 4265 - 4274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-M. Cho, J. D. Rosenblatt, Y.-S. Kang, M. L. Iruela-Arispe, S. L. Morrison, M. L. Penichet, Y.-G. Kwon, T.-W. Kim, K. A. Webster, H. Nechustan, et al. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein Mol. Cancer Ther., June 1, 2005; 4(6): 956 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Baselga and C. L. Arteaga Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer J. Clin. Oncol., April 10, 2005; 23(11): 2445 - 2459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Pegram Molecular Determinants of Trastuzumab Response/Resistance Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 155 - 159. [Full Text] [PDF]
|
|
|
|
|
|
A. Hamilton and G. Hortobagyi Chemotherapy: What Progress in the Last 5 Years? J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775. [Full Text] [PDF]
|
|
|
|
|
|
Y. Nieto, J. J. Vredenburgh, E. J. Shpall, S. I. Bearman, P. A. McSweeney, N. Chao, D. Rizzieri, C. Gasparetto, S. Matthes, A. E. Baron, et al. Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer Clin. Cancer Res., November 1, 2004; 10(21): 7136 - 7143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Perez Carboplatin in Combination Therapy for Metastatic Breast Cancer Oncologist, September 1, 2004; 9(5): 518 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Sledge Jr. HERe-2 Stay: The Continuing Importance of Translational Research in Breast Cancer J Natl Cancer Inst, May 19, 2004; 96(10): 725 - 727. [Full Text] [PDF]
|
|
|
|
|
|
M. D. Pegram, T. Pienkowski, D. W. Northfelt, W. Eiermann, R. Patel, P. Fumoleau, E. Quan, J. Crown, D. Toppmeyer, M. Smylie, et al. Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer J Natl Cancer Inst, May 19, 2004; 96(10): 759 - 769. [Abstract] [Full Text] [PDF]
|
|